HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC
May 01, 2024 17:00 ET
|
HiberCell, Inc.
HiberCell Announces FPD in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with ccRCC
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
April 05, 2024 10:00 ET
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
HiberCell Announces Presentation at ASH, Highlighting Preclinical Data for HC-7366 with Standard of Care Agents in Acute Myeloid Leukemia (AML)
December 15, 2023 10:00 ET
|
HiberCell, Inc.
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced...
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)
December 05, 2023 10:00 ET
|
HiberCell, Inc.
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan)
HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations
November 27, 2023 09:53 ET
|
HiberCell, Inc.
HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of HC-5404 and Maps Forward Path as Monotherapy and in Combinations
HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting
May 22, 2023 16:00 ET
|
HiberCell, Inc.
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced dosing of...
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 24, 2023 07:00 ET
|
HiberCell, Inc.
BOSTON, March 24, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis, treatment resistance, and cancer...
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)
February 22, 2023 08:00 ET
|
HiberCell, Inc.
In vitro and in vivo results demonstrated HC-7366 is a potent GCN2 activator with strong antitumor activity in AML as a single agent and in combination with venetoclax; data supports further clinical...
HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 02, 2022 16:01 ET
|
HiberCell, Inc.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
May 24, 2022 08:00 ET
|
HiberCell, Inc.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced...